Men’s health clinics across the country market shockwave therapy as a treatment for Peyronie’s disease – a condition where fibrous scar tissue (plaque) develops inside the penis, causing curvature, pain, and sometimes erectile difficulties. The marketing often features dramatic claims about “dissolving plaque” and “restoring normal anatomy.”

The actual evidence tells a more nuanced story. If you’re dealing with Peyronie’s disease, you deserve an honest assessment of what extracorporeal shockwave therapy (ESWT) can and cannot do – separate from the sales pitch.

Understanding Peyronie’s Disease

Peyronie’s disease affects an estimated 3-9% of men, though many cases go unreported. It involves the formation of fibrous plaque in the tunica albuginea (the tough outer layer of the penis), which creates curvature, shortening, and sometimes painful erections.

The disease has two phases:

  • Active (acute) phase: Pain during erections, progressive curvature change, plaque formation. Lasts 6-18 months.
  • Stable (chronic) phase: Curvature stabilizes, pain typically resolves, but the structural changes remain.

Standard treatments include:

  • Observation during the active phase (curvature may stabilize or occasionally improve)
  • Collagenase injections (Xiaflex) – the only FDA-approved medication for Peyronie’s curvature reduction
  • Penile traction therapy – mechanical stretching devices with some evidence for curvature improvement
  • Surgery – the most effective option for stable-phase disease with significant curvature (plication, grafting, or penile prosthesis)

What ESWT Proponents Claim – and What the Evidence Shows

The theoretical basis for using shockwave therapy in Peyronie’s disease is straightforward: acoustic pressure waves might break down fibrous plaque, promote tissue remodeling, and reduce the structural deformity. It sounds logical. But the clinical evidence has not consistently supported these claims.

Pain Improvement: Modest Evidence

Several studies suggest ESWT may reduce pain associated with Peyronie’s disease, particularly in the active phase. A 2004 study by Hauck et al. (European Urology) found significant pain reduction in the ESWT group compared to placebo. This is consistent with ESWT’s well-documented analgesic effects across other conditions.

Curvature Reduction: Weak Evidence

This is where the evidence falls short. Multiple studies – including a well-designed randomized controlled trial by Chitale et al. (2010, International Journal of Clinical Practice) – found no significant difference in penile curvature between ESWT and placebo groups. A 2019 systematic review in the Journal of Sexual Medicine reached a similar conclusion: ESWT does not appear to meaningfully reduce curvature or plaque size.

Plaque Size Reduction: Insufficient Evidence

Claims about ESWT “dissolving” plaque are not supported by the current data. While some case series have reported subjective improvements, controlled studies have not demonstrated consistent, measurable plaque reduction.

How This Differs from Shockwave Therapy for ED

It’s critical to understand that shockwave therapy for erectile dysfunction and shockwave therapy for Peyronie’s disease are different applications targeting different pathologies with different protocols.

  • ED protocol: Low-intensity shockwave therapy (Li-SWT) targets penile vasculature to stimulate blood vessel growth and improve blood flow. The evidence here is more promising, with multiple RCTs showing improvements in erectile function scores.
  • Peyronie’s protocol: ESWT targets the fibrous plaque itself, attempting to break it down through mechanical energy. Different energy settings, different anatomical targets, different expected outcomes.

Clinics that blur these two applications in their marketing are doing patients a disservice. Reviewing the latest shockwave therapy research can help you understand where the evidence is stronger versus weaker.

Red Flags in Marketing

Be cautious of clinics that:

  • Guarantee curvature correction from ESWT alone (not supported by evidence)
  • Use before-and-after photos without context about other concurrent treatments
  • Charge premium prices ($3,000-$10,000) for ESWT packages positioned as Peyronie’s “cures”
  • Fail to mention FDA-approved alternatives like Xiaflex or surgical options
  • Combine ED and Peyronie’s marketing as if they are the same treatment

A reputable provider will be transparent about ESWT’s limitations for Peyronie’s disease and discuss all evidence-based options, including those with stronger support.

Where ESWT Might Have a Role

Despite the limitations, ESWT may have a narrow role in Peyronie’s management:

  • Pain management during the active phase, where its analgesic effects have some evidence
  • Adjunctive use alongside other treatments (traction therapy, Xiaflex) – though combination data is sparse
  • Patient preference for a non-invasive approach when the primary concern is pain rather than curvature

If you’re exploring this option, seek a urologist who specializes in Peyronie’s disease rather than a general men’s health clinic. A provider who is upfront about these distinctions is the kind of provider worth trusting.

The Bottom Line

Shockwave therapy for Peyronie’s disease may help with pain, but evidence for its ability to reduce curvature or plaque size is weak. The aggressive marketing around this application often overstates what the research supports. Patients with Peyronie’s disease should discuss all evidence-based options – including Xiaflex, traction therapy, and surgery – with a qualified urologist before committing to ESWT.

Explore our condition guides to learn more about evidence-based shockwave therapy applications.

References

  1. Hauck EW, Mueller UO, Bschleipfer T, Schmelz HU, Diemer T, Weidner W. Extracorporeal shock wave therapy for Peyronie’s disease: exploratory meta-analysis of clinical trials. J Urol. 2004;171(2 Pt 1):740-745. PubMed

  2. Chitale S, Morsey M, Swift L, Sethia K. Limited shock wave therapy vs sham treatment in men with Peyronie’s disease: results of a prospective randomized controlled double-blind trial. BJU Int. 2010;106(9):1352-1356. PubMed

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Shockwave therapy outcomes vary by individual and condition. Consult a qualified healthcare provider to determine if shockwave therapy is appropriate for your situation.